Evening of Innovation

 Murrieta Genomics is dedicated to finding those answers and advancing  the use of genomic sequencing in precision medicine, agriculture,  forensics, veterinary and direct to consumer applications by offering  entrepreneurs access to the specialized equipment, know-how and mentors  that can transform research into commercial enterprise. 

 SimplSeq has developed a proprietary process to prepare biological  samples for next generation genomic sequencing processing that will save  thousands of labs a great deal of time and expense. While the time and  cost of the sequencing of DNA and RNA has dropped substantially, the  process of extracting DNA or RNA from a biological sample, purifying it,  and making enough copies to get a good read has basically remained the  same. 

GattaCo Inc. is a young Southern California startup company that develops solutions for the life science and medical industry.

  GattaCo’s  mission is to enable next generation diagnostics and simplified sample  collection and processing. We do this by leveraging our patented  Capillary Pressure Re-Set (or Cap-Reset™) Technology to create novel  products and solutions for our partners.   

Swellter is a patient immersion platform that is enriching the oncology  patient-provider experience through consent, education, and data sharing  in real-time. Swellter opens a window through which laboratory and  pharmaceutical companies can share relevant and potentially  transformative diagnostic and therapeutic options with oncologists and  cancer patients. We are steadfast in building a transformative platform  that will change the patient experience and engage all oncology  stakeholders.

Neyroblast GX's focus is to develop next-generation theranostic products for  neurodegenerative and infectious diseases like Alzheimer’s disease and  COVID-19. We also have a platform to provide custom-made human organoids  and genetically engineered cells for screening drug, toxicity, and  disease pathology. Our team of scientists comes from a range of  backgrounds across academia, biotech, and pharma with extensive  experience in nutraceutical biomedicine, genetics, neurobiology, drug  develop

Parthen, Inc. was formed in 2021 to utilize advances in genomic sequencing and telehealth technologies in order to provide a patient-centered approach to precision cancer care.

Virtually everyone’s life has been affected by cancer in one way or another, but we are never prepared for that moment when we ourselves are diagnosed with the disease. It is a gut-wrenching moment that fills one with dread and fear. 

Parthen wants to provide a “comfort zone” for patients, where they can get answers to th

TX Genetic Research offers personalized health and wellness services and products based on an individual's whole exome sequencing (WES) genetic profile and their health symptoms.

TRIO  Pharmaceuticals, Inc. is a cancer immunotherapeutics company pioneering  dual action drugs to generate immunogenic tumors. TRIO's innovative  antibody drugs directly stop tumor growth and selectively stop  immunosuppression in the tumor without targeting the current immune  checkpoint pathways. TRIO is developing a proprietary platform of dual  action tumor immunity-enhancing drugs aimed at treating cancers of high  unmet medical needs by targeting specific antigens on the cancer cells  an

Gnomegen focuses on clinical ready reagent, consumable and instrument development. Gnomegen’s current pipeline of products are based on digital PCR and next generation sequencing. Alongside COVID-19 EUA kit, Gnomegen will continue develop and register additional FDA products on viral and liquid biopsy detection. 

EpigeneticsRx offers a comprehensive set of tools allowing physicians and their patients to have everything they need in one place for precise, personalized, preventative healthcare.